Health Canada Allows Acasti Pharma to Initiate CaPre Phase II Trial

Health Canada has approved Acasti Pharma’s clinical trial application (CTA) to commence a Phase II trial of CaPre. Following the approval, the company expects to start a double blind, placebo controlled and randomized Phase II trial to assess the usage of CaPre for the treatment of patients with dyslipidemia.
PBR